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Background: Uncooked corn-starch (UCCS) has been the mainstay of therapy for the hepatic glycogen storage diseases
(GSD) but is not always effective. A new starch (WMHMS) has demonstrated a more favourable short-term metabolic profile.
Objective: To determine efficacy and safety of a new uncooked starch (WMHMS) compared to UCCS over 16 weeks
treatment with each.
Method: A double-blind cross-over study of 10 adults (aged 16 – 38 years, six male) with GSD Ia and Ib. After an
individualised fast, subjects were randomised to take a 50 g starch-load of either WMHMS or UCCS. Starch-loads
terminated when blood glucose was < 3.0 mmol/L or the subject felt subjectively hypoglycaemic. Anonymous
biochemical profiles were assessed by 2 investigators and a starch administration schedule recommended. Each
starch was delivered in coded sachets and intake was monitored for the following 16 weeks. After a washout period,
the protocol was repeated with the alternative product.
Results: 4 subjects failed to establish therapy on the cross-over limb. Data from 7 paired starch load showed:
longer median fasting duration with WMHMS (7.5 versus 5 hours; p = 0.023), slower decrease in the glucose curve (0.357
versus 0.632 mmol/hr p = 0.028) and less area under insulin curves for the first 4 hours (p = 0.03). Two of six
subjects took 50% or less WMHMS compared to UCCS and one took more. Plasma triglycerides, cholesterol and uric acid
were unchanged after each study phase.
Conclusion: WMHMS leads to significant reduction in insulin release and reduced starch use in some GSD patients.
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Waxy maizeBackground
The glycogen storage diseases (GSDs) comprise a group of
rare inherited disorders of glycogen metabolism. GSD I
(OMIM 232200) is caused by reduced activity of glucose-
6-phosphatase (G6Pase, EC 3.1.3.9); GSD Ia by deficiency
of the hydrolytic enzyme; and GSD Ib by deficiency of* Correspondence: Kaustuv.Bhattacharya@health.nsw.gov.au
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6-phosphate transport protein, G6P translocase. The major
metabolic consequence of ineffective function of G6Pase is
hypoglycaemia, provoked by relatively short fasts. Secondary
metabolic disturbances include hyperlactataemia, hyper-
uricaemia and hyperlipidaemia [1].
Maintaining blood glucose concentration in the normal
range improves secondary biochemical features as well as
clinical parameters such as growth. The introduction of
continuous nasogastric glucose polymer feeds showed this
clearly [2,3]. The subsequent introduction of uncooked
corn-starch (UCCS) into the daily dietary treatment at leastentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of many patients [4,5]. Whilst the introduction of UCCS has
benefited many, its use does have problems. For some the
duration of normoglycaemia can be less than 4 hours, many
find the mixture neither palatable nor convenient, and for
others there can be symptoms of bloating, flatulence and
diarrhoea with large doses [6]. UCCS is only partially utilized
and can be associated with malabsorption in GSD I. [7].
Diarrhoea may also be a feature of GSD I itself or its treat-
ment with corn-starch, and inflammatory bowel disease is a
feature of GSD Ib [8].
Apart from sustained normoglycaemia without excessive
insulin rise, the features of an ideal starch for treatment of
patients with the hepatic GSDs include suppression of sec-
ondary biochemical abnormalities, palatability, conveni-
ence, few side-effects and maintenance of normal appetite
(without excessive weight gain [9,10].
A heat modified waxy maize starch (WMHM20),
(Glycologic Ltd, Glasgow, UK), prepared in an emulsified
form (WMHMS) (Vitaflo Ltd, Liverpool, UK) has shown
improvement in the duration of normoglycaemia and
glucose profile in particular of patients with glycogen
storage disease type Ia and Ib, [11,12], but there are no
data reported on the sustained use of the starch in the
normal dietary regimen. This trial investigated the use of
this starch (WMHMS) in the daily dietary regimen of
adults with glycogen storage disease type Ia and Ib over
16 weeks.
Methods
The study protocol was approved by the ethics committee
nominated by the UK Central Office for Research Ethics
Committees (COREC). All adults that attended the
Charles Dent Metabolic Unit clinic, London UK with a
enzymatic and/or molecular proven diagnosis of GSD Ia or
Ib, that were taking uncooked corn-starch as part of their
dietary regimen were invited to participate. All recruited
subjects gave written informed consent to participate.
The study had a randomised double-blind cross over de-
sign. Subjects were allocated an anonymous reference num-
ber and were randomly allocated to receive either UCCS or
WMHMS. Each starch was manufactured using food-grade
techniques and packaged in identical sachets bearing a
reference code. The patient reference numbers and sachet
reference code were paired by Vitaflo Ltd and the supervis-
ing physicians (KB, FM) were blinded to this pairing. The
supervising physicians devised a safe personalised fasting
period for each patient, prior to each starch load based on
previous corn-starch loads and medical history.
Starch load test
Patients attended in the morning after their individua-
lised fast. An intravenous cannula was placed in the pa-
tient’s arm and baseline blood samples were collected.When the participant’s blood glucose was below
4.5 mmol/L, 50 g of the nominated starch mixed in cold
water was taken orally. Blood samples were performed
at 30 minute intervals for the next 120 minutes and
hourly thereafter. No further intake, apart from drink-
ing water, was allowed. The starch load test ended when
the patient had fasted for 10 hours, the plasma glucose
was ≤3.0 mmol/L on the bedside glucose analyser (YSI
2300 - Yellow Springs, Ohio, USA) or the patient wished to
end the test. When the blood glucose was ≤ 3.5 mmol/L,
blood tests were performed at 30 minutes intervals until
the test end.
Biochemical data
Plasma was extracted from whole blood samples immedi-
ately at the bedside. Plasma glucose and lactate were ana-
lysed immediately (YSI 2300 - Yellow Springs, Ohio, USA).
Serum to measure insulin was frozen within 30 minutes of
collection and subsequently thawed and analysed by a
solid-phase, two-site chemiluminescent immunometric
assay (Immulite 2000, Diagnostic Products Corporation,
Los Angeles, USA). At baseline, “fasting” cholesterol, tri-
glycerides and uric acid were taken.
Repeat starch load
Data from the first starch load was used to guide man-
agement using the particular starch for the subsequent
16 weeks. After a further washout period of 2 – 4 weeks
on normal treatment, participants re-attended for a
further starch load with the alternative starch.
Prescription of starch
The glucose and lactate data from the load test were
interpreted by two investigators who have experience in
interpreting these results (PJL and MPC). Neither of
these investigators had any other subject-related role in
the study. They were blinded to the identity of both the
participant and the starch. They were given some back-
ground information of normal starch dosing and the last
available corn-starch load data for that participant. On
the basis of this information a safe frequency of daytime
dosing for the given starch was discussed, agreed and
prescribed. The participants were asked to take the
nominated starch for 16 weeks. If the volunteer took an
overnight infusion of glucose polymer, this was not
altered.
Delivery of starch
The starch was delivered in boxes with individual
sachets bearing a reference code identifying the type of
starch only to representatives from Vitaflo Ltd. The par-
ticipants were asked to take the nominated starch as
recommended by the blinded prescribers. However, it is
recognised that some patients take less or more starch
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asked to note what they actually took and this was noted
by a telephone call made by one member of the research
team on a weekly basis.
Monitoring of starch use and symptoms
For the 16 week study period, participants were asked to
keep a record of subjective episodes of hypoglycaemia.
Whilst measurement of blood glucose was not recom-
mended, participants were also asked to keep a record of
any blood glucose measurement that was taken. One
member of the research team contacted the participant
to note these data as well as general information about
symptoms and appetite over the preceding week. If the
participant had an inter-current illness such as diarrhoea
or vomiting necessitating additional glucose polymer use
or was admitted to hospital for intravenous dextrose, the
entire week’s data for this period was omitted from ana-
lysis. A maximum of 2 consecutive weeks and 4 total
omitted weeks were allowed, from each 16 week period,
to remain included in the trial. The participant was
asked to complete a diet diary after they had taken the
nominated starch for at least 6 weeks. They were asked
to write down everything they ate for a 3 day period and
the nutritional content of the diet including the starch
taken were analysed by an experienced state registered
dietician (MFL) using specialised software (Dietplan 6,
Forestfield Software, Ltd. Horsham, UK.)
End of study period
At the end of the 16 week study period, the research
volunteer was asked to attend an outpatient clinic. They
were weighed and examined and “fasting” plasma tri-
glycerides, cholesterol and uric acid were taken. This was
followed by a washout period of 2 – 4 weeks and the
patient re-attended for a starch load with the alternative
starch. Pre-starch-load preparation including fasting
period and assessments were identical. The subject was
asked to take the same meals at the same times the day
before the second starch-load as they had for the first one.
Statistics
Data were entered into GraphPad Prism software (version
5.02, La Jolla, California.) All analyses were two-tailed. Test
durations were compared both paired and unpaired by
Wilcoxon’s sign rank test and the unpaired data plotted on
a Kaplan-Meier curve as shown in Figure 1. The one
subject that fasted for 10 hours without evidence of
hypoglycaemia was right censored for that starch load.
Given the small number of subjects, paired non-parametric
analyses (Wilcoxon sign rank test) were used to compare
glucose, lactate and insulin profiles. Similarly, areas under
the insulin and glucose curve for each individual for the
first 4 hours for each starch were compared by paired non-parametric analyses. Areas under the curve were calculated
for each patient by GraphPad Prism and checked inde-
pendently manually by another researcher (DJW). The first
four hours of the starch load were used as a cut-off for area
calculations for two reasons: a) the mean profile for glu-
cose “cross-over” at this time point with the WMHMS
curve were lower than UCCS in the first four hours and
higher subsequently (Figure 2) – this has also been noted
previously (Bhattacharya et al [11]), and subjects withdrew
due to hypoglycaemia after four hours and there were con-
sequently incomplete paired data after this time-point.
Weekly quantity of starch intake was compared by a
two tailed paired t-test for each individual. Total energy
intake and energy intake derived from both treatment
and dietary carbohydrate were obtained from analyses of
dietary diaries and compared by paired non-parametric
analyses (Figure 3), as was the difference from baseline of
monitoring biochemistry (Table 1). Data were considered
statistically significant when p < 0.05.
Results
10 volunteers were recruited to the study. Patient details
are shown in Table 2 and the disposition of recruited
patients indicated in Figure 1. A total of 4 patients with-
drew from the trial protocol of which 3 did not have a
repeat starch load. Paired data were therefore available
for 6 subjects taking each product for 16 week phase of
the trial and for 7 starch loads.
Adverse events
Whilst on UCCS, 4 of 8 subjects were admitted into hos-
pital – all for reasons not deemed to be trial related – one
for dysphagia related to a substance ingested by mistake, a
second one for haematuria and abdominal pain probably
related to a renal stone (this subject withdraw from the
second limb of the study on WMHMS) and the remaining
two for vomiting associated with hypoglycaemia during an
inter-current viral illness. Whilst on WMHMS, 1 subject
with GSD Ib was admitted twice to hospital, firstly with
post streptococcal glomerulonephritis and secondly with a
viral lower respiratory tract infection (this subject subse-
quently withdrew without taking UCCS), and the compli-
cations not deemed to be trial related.
Starch loads
8 starch loads were performed using UCCS with a median
duration of 5 hours and 9 starch loads with WMHMS
with a median duration of 7.5 hours (p = 0.0091, ratio
0.67, CI of ratio 0.29,1.04. – Figure 2). When only the 7
paired starch loads are considered, the median durations
remain the same and the comparison were still statistically
significant, (p = 0.023). The mean glucose and insulin pro-
files are indicated in Figure 3. The insulin curve for
WMHMS was below the UCCS curve for most of the
Figure 1 Indicating trial outline and withdrawals.
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Figure 2 Kaplan Meier curve indicating test durations for all
starch loads performed: n=8 for UCCS and n = 9 for WMHMS.
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reflecting the fact that the glucose curve for WMHMS
was also below UCCS for the first 4 hours of the study
(p = 0.016) and then was higher than the UCCS curve.
There was a trend for the area under the WMHMS glu-
cose curve to be lower; the median area and inter-quartile
range of the area above a baseline of 3.0 mmol/L for
WMHMS being 5.36 mmol/L hrs (3.56 – 8.12,) and forFigure 3 Mean (+ /- SD) profile for seven paired starch loads for a) gl
under the curve for the first four hours of the study for c) glucose and d) i
given time, T in hours, for C = UCCS and W = Waxy maize heat modified sUCCS being 7.20 mmol/L hrs (6.01 – 9.86) (p = 0.10) for
the first four hours of the study. Similarly the area under
the insulin curves was significantly lower for WMHMS,
being 114 pmol/L hrs (70.1 – 289) compared to UCCS
being 386 pmol/L hrs (123 – 415) (p = 0.031), as indicated
in Figure 3. Similar to previous studies, there was no dif-
ference between either the lactate profile or the area under
the lactate profile for the first four hours: WMHMS being
21.9 mmol/L hrs (8.25 – 34.6) and UCCS 18.3 mmol/
L hrs (16.8 – 27.2), (p = 0.47).
Use of starch during trial
Mean weekly starch use by the 6 patients that completed
the study is shown in Figure 4. Whilst the differences for
the group are not statistically significant, 2 subjects did
take significantly less WMHMS than UCCS when their
weekly intakes were compared by paired t-tests (920 g vs
2600 g), and (980 vs 2100 g), p < 0.001 for both. One
subject took more WMHMS than UCCS (1020 g vs
690 g p < 0.001), but this was related to better compli-
ance with prescribed therapy after she was notified in
the washout period about deteriorating long-term renal
function. This was substantiated by an increase of 4.3 Kg
weight over the washout period on normal therapy prior
to starting WMHMS. The reduction of starch use in twoucose and b) insulin. The median and interquartile range of areas
nsulin. Table for 3a and b indicates number of subjects still fasting at a
trach. (Glucose area calculated above a baseline of 3.0 mmols/L).
Table 1 Biochemical monitoring of six patients that completed both phases of trial indicating median baseline value
and median change from baseline
Triglycerides (mmol/L) Cholesterol (mmol/L) Uric acid (μmol/L) ALT IU/L CRP mg/L
Baseline 3.62 4.7 402 38.6 5
WMHMS Median change 0.22 0.29 -41 -9 0
Baseline 5.12 5.35 364 36.8 11
UCCS Median change -1.57 -0.5 -58 -13 -3
Normal Range 0.42 - 2.00 3.35 - 6.2 149 - 369 <50 <10
Statistic (p value) 0.56 0.19 0.84 0.84 0.44
Paired non parametric analyses of the change from baseline for each individual were performed to produce the statistic indicated in bold. (ALT: Alanine
transaminase; CRP: C-reactive protein).
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broadening of dietary intake. As a consequence their
total energy intake reduced from 2410 and 3044 Kcal/
day to 1876 and 2454 respectively. There was no differ-
ence in median weight change between the 2 popula-
tions: + 0.25 Kg for WMHMS and – 0.05 Kg for UCCS.
Patient specific data is indicated in Table 3. Those that
took less WMHMS lost weight. Two patients gained
over 6 Kg of weight taking WMHMS; patient B was
more compliant with diet after receiving adverse GFR
tests results in the wash-out period and consequently
took approximately 150% of the amount of starch in the
second phase of the study on WMHMS. Patient E found
WMHMS unpalatable adding chocolate powder to this
and not to UCCS leading to weight gain on the WMHMS
phase. Biochemical monitoring was also satisfactory as
shown in Table 1. Symptoms that were monitored on a
weekly basis were general well-being, appetite, abdominal
bloating, diarrhoea, symptomatic hypoglycaemia and mea-
sured hypoglycaemia. For the whole group, there was no
difference in all parameters but there were some individ-
ual variations. One patient was more bloated with UCCS,
but this subject took more UCCS than WMHMS, and the
bloated sensation may have reflected increased total starch
intake. There was no difference with other patients. Sev-
eral patients reported marginally improved appetites on
WMHMS, but this was not substantiated by objective
assessments of dietary records. Of the 9 subjects that had
taken WMHMS in this study, 7 opted to continue therapy
after the trial concluded. Table 2 indicates whether the
blinding was successful and in some cases it wasn’t.
Several of the patients commented on the texture and
mouth-feel of WMHMS being different to UCCS with a
more gritty texture to that which they were habituated to.
Some patients recognized and overcame this texture
difference whilst others didn’t and withdrew.
Discussion
The dietary regimen for the treatment of type I glycogen
storage disease has previously been called the “intensiveregimen”, with hypoglycaemia a predominant feature
after even quite short fasting intervals [13,14]. For some,
the intensive regimen has improved after the introduc-
tion of uncooked corn-starch, but for others fasting tol-
erance can still be as little as 4 hours. As a consequence
several need disruptive overnight doses of starch. Several
patients can have gastrointestinal disturbances including
bloating flatulence and diarrhoea [15,16]; colonic fer-
mentation of unutilised corn-starch could be partly
responsible for this in both GSD Ia and Ib, although in-
flammatory bowel disease is a well-recognised feature of
GSD Ib [8].
Glycemic Load of WMHMS
Waxy maize starch differs from typical corn-starch in
that it has a high proportion of amylopectin. It has been
subject to research interest due to its low glycaemic
index [17]. Chemical or physical modification appears to
alter the physiological responses further [18,19]. Using
this type of approach, our research group was able to
demonstrate a longer median duration of normogly-
caemia for patients with GSD with a heat modified waxy
maize starch compared to uncooked corn-starch [11].
However, this study was confounded by several factors
including the age, type of GSD and precision of bedside
glucose measurements. As a consequence the most
meaningful result was that the glucose decreased slower
with the new starch compared to traditional uncooked
corn-starch. These findings were sufficient to trigger an-
other independent study, which has replicated these data
[12]. Methodologically the latter study tested a more
homogeneous group of patients at rest overnight,
thereby limiting energy expenditure. Both studies aimed
to use large doses to gauge whether a single night time
dose would suffice for metabolic homeostasis. The
current study differed in that smaller doses were used
(50 g in adults– 41 g of carbohydrate), that could be incor-
porated into the standard daytime dietary regimen. Com-
pared to our previous study, a more homogeneous group
of patients were selected in that all were adults with GSD
Table 2 Demographics of patients, indicating normal daily therapy and whether they were successfully blinded in this study
ID Age (yrs) Sex GSD type BMI Normal starch treatment Medications Complications Blinding success
A 23 M 1a 21.8 D – 120 g UCCS N –125 g polymer Allopurinol,Ramipril, Carbamazepine
Multivitamins
Seizures (stable) Yes
B 24 F 1a 26.0 D – 60 g UCCS N – 55 g UCCS Allopurinol, Ramipril. Vit B12 PCOD Renal impairment No – able to tell difference of taste.
C 25 F 1a 26.7 D – UCCS 160 g N - 120 g Polymer Allopurinol Multivitamins PCOD Yes
D 38 M 1a 22.3 D –UCCS 200 g N – UCCS 100 g Allopurinol simvastatin,
codeine, lansoprazole
Hepatic adenoma (removed)
Chronic scar pain Heartburn
No – took much less WMHMS than UCCS
E 16 M 1b 27.1 D – 160 g N – 175 g polymer Allopurinol None No – Did not like taste of WMHMS
to start but habituated
F 17 M 1b 34.6 D – 120 g N – 140 g polymer Allopurinol Obese Yes – Thought UCCS was test starch.
G 19 F 1b 25 D – 90 g N – 120 g Polymer Allopurinol GCSF Anaemia Recurrent infections No – able to detect different texture
H 18 F 1b 24.9 D – 180 g N – 120 g Allopurinol, GCSF Co-trimoxazole
Thalidomide
GSD IB enterocolitis Bronchiectasis No – withdrew as did not like taste of WMHMS
I 24 M 1b 19.7 D – 160 g N – 80 g Allopurinol GCSF Short stature Diarrhoea No – took much less WMHMS than UCCS.
J 36 M Ib 22.2 D- 30 g N- 30 g Allopurinol Ferrous sulphate Hepatic adenoma Chronic anaemia No – had fewer episodes of diarrhoea
with WMHMS and refused to take UCCS














Figure 4 Mean weekly trial starch use over 16 weeks for 6
patients with paired data. Median of these indicated by bold line.
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were available at the bed-side. The combination of these
and other factors have resulted in this study being better
able to define the glucose and insulin responses to each
starch load. Of note, the studies of Jenkins et al that de-
fined glycaemic index indicated that greater relative differ-
ences in glycaemic index were observed when 50 g of a
carbohydrate was used compared to 100 g [20]. These
studies used frequent glucose measurements over 120 mi-
nutes with subjects fasting in a standardised way before
the carbohydrate was administered. We also attempted to
control baseline by administering the starch when the
plasma glucose was below 4.5 mmols/L and sampled at
30 minute intervals for the first 120 minutes. There was
consequently better resolution of the glycaemic response
compared to the other studies of this starch in GSD. The
significantly reduced area under the insulin curve using
WMHMS is consistent with the lower glucose curves in
the first four hours, with subsequent slower decline in glu-
cose. As mentioned by Correia et al, this is a safer profile
with a lesser tendency to sudden hypoglycaemia. The aim
of researchers that manage GSD is to extend the period of
normoglycaemia rather than decrease the early insulin re-
sponse to carbohydrate ingestion, but it is clear for thisTable 3 Weight in Kg before and after the 16 week phase of
over the period indicated
ID First Pre Post Post UCCS
Starch UCCS UCCS - pre Use g/w
A W 57.8 58 0.2 1033
B U 63.2 60.8 -2.4 688
C U 77.6 76.4 -1.2 1480
D U 55 59.6 4.6 2648
E U 73.1 72.8 -0.3 702
I W 50.3 52.3 2 2100
The amount of treatment starch taken in grammes per week is also shown in bold.
patient was first randomized to is indicated in the second column. W = WHMHMS astarch that the latter affects the former. The duration of
normoglycaemia was longer for the new starch com-
pared to UCCS replicating the findings of the studies
using higher doses. However, this finding should not be
over-interpreted as some individuals wished to end the
test before documented hypoglycaemia was identified.
As in previous studies with GSD, this probably occurs be-
cause patients are unfamiliar with fasting for 7 hours or
greater and could consequently feel insecure. However, if
replicated, this should translate in to fewer starch doses
taken by individuals and less overall starch use.
Methodological difficulties
Only two individuals took significantly less WMHMS
than UCCS over the course of this study. Part of the rea-
son for this was because of the safety aspect of the study
design. Three individuals that took overnight pump
feeds of glucose did not have this aspect of their treat-
ment altered. Consequently, there was a reduced period
of 14 or 15 hours in which any dose of studied carbohy-
drate could be taken. The only real options in that time
period were to prescribe either two doses at 7 hour in-
tervals or three doses at 4 – 5 hour intervals; for each of
these patients, the more conservative 4 hourly regimen
was selected for both starches, even if the data suggested
someone could fast for six hours comfortably. These
subjects, who place naso-gastric tubes themselves every
night, were particularly compliant, only ever taking more
than the prescribed dose, but never less. Therefore, no
difference is seen for these 3 individuals. By contrast, the
3 subjects who take corn-starch both day and night had
more flexibility with prescriptions and also varied the
amount they took more. Two of these three subse-
quently took significantly less WMHMS and the other
subject complied more with the prescribed dose due to
adverse long-term deterioration in renal function.
Further studies
The mechanism of potential extended duration of
WMHMS needs more investigations. Our previouseach starch treatment with change of weight indicated
Pre Post Post WMHMS
eek WMHMS WMHMS - pre Use g/week
56.7 57.7 1 1047
65.1 72.2 7.1 1018
76.5 76 -0.5 1478
59.5 55 -4.5 920
73.6 80.5 6.9 703
53.2 50.4 -2.8 983
See text for explanations of individual differences. The starch to which the
nd U = UCCS.
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UCCS, confirming previous findings, but this was not
matched by increased enrichment of 13CO2 with
WMHMS. This may have been confounded by the age
range of subjects and the variable duration of tests. Sus-
tained incretin release after UCCS ingestion has been
shown when compared to other carbohydrates. This
may also account for increased insulin release when
UCCS is compared to waxy maize starch [21]. There are
also natural enrichment data demonstrating delayed
gastric emptying of waxy maize starch when compared
to other carbohydrates [17]. It is probable, but not def-
inite, that the heat modified waxy maize starch behaves
more like its native starch than UCCS. As such, delayed
gastric emptying and diminished insulin release are po-
tential mechanisms of action. The role of appetite sup-
pression modulated by adiponectin and the ghrelin and
leptin axis has not been sufficiently studied in GSD. It is
possible, in these fasting GSD studies, that patients
mistake hunger for hypoglycaemia because patients are
unfamiliar with prolonged fasting and its associated
physiology.
WMHMS in healthy volunteers
WMHMS has now been studied in healthy volunteers
allowing its role to be investigated under different
physiological stresses to patients with GSD. Roberts et al
studied 9 male competitive cyclists during and after in-
tense exercise [22]. They compared WMHMS with
maltodextrin finding decreased insulin production and
increased fat oxidation in the former group. Bracken et
al compared WMHMS (Glycosade TM) with UCCS
(Argo TM) and dextrose at rest, followed by an hour of
exercise and a subsequent 2 hour recovery period [23].
In the resting phase, peak glucose concentration oc-
curred later with WMHMS compared to UCCS and
there was evidence of increased lipid oxidation during
exercise too. Conversely, there was equivalent increased
carbohydrate oxidation in exercise of UCCS and dex-
trose compared to WMHMS. It is very difficult to ex-
trapolate these data to the GSD population. Firstly it is
important to discriminate whether glucose oxidation is
from endogenous or exogenous sources – if the increased
carbohydrate oxidation is endogenous, this would be im-
paired in GSD and lead to compromise. Conversely, some
individuals with GSD appear to have impairment in ke-
tone body production so increased lipid oxidation may
not be replicated in GSD patients [24].
Context of these data in patients
The significant lifelong carbohydrate intake that these
patients take put them at particular risk of insulin resist-
ance and non-insulin dependent diabetes mellitus, al-
though there are few reports of these complications [25].Data from our dietary surveys demonstrate that some
patients take more carbohydrate than recommended for
the population and theoretically required in GSD pa-
tients [24]. There is also a tendency of some individuals
to take higher glycaemic index commercially available
drinks to prevent or treat hypoglycaemia. This results in
additional fluctuation of glucose and insulin over and
above that caused by prescribed dietary products. Com-
plications such as hyperlipidaemia, hepatic steatosis and
polycystic ovarian disease are well recognised features of
the hepatic glycogenoses and it is likely that insulin re-
sistance plays some part in the pathophysiology of such
[6,26-28]. Long-term reduction in insulin release by
using a starch such as WMHMS may therefore result in
health benefits, although data need to be prospectively
gathered over many years to substantiate this. Quite
apart from having benefits for GSD-I patients, WMHMS
may be of benefit in other disorders that require sus-
tained euglycaemia without excessive insulin release.
The dietary treatment of diabetes mellitus could well
benefit from this therapy, but again this needs to be
tested independently. Other inborn errors of metabolism
associated with hypoglycaemia may also benefit from
this treatment. The role of WMHMS in fat oxidation de-
fects needs to be cautiously evaluated as insulin release
may be protective in these disorders.
Conclusion
This study with a small number of patients with GSD Ia
and Ib, demonstrated that WMHMS can be safely incor-
porated into the dietary regimen of these patients. Our
experience shows that these patients are a difficult group
to study. From a metabolic perspective, they are brittle
with a tendency for hypoglycaemia after very short fasts
with marked fluctuation of related variables, insulin
and lactate, as well as longitudinal indices of metabolic
control such as triglycerides and uric acid. These study
difficulties have been commented on specifically on a
meta-analysis of GSD Ia dietary therapy [29]. Co-
morbidities such as diarrhoea, renal stones, renal im-
pairment, inflammatory bowel disease and recurrent
infections need to be taken into account for long-term
studies and hospitalisations are not infrequent as was
observed in this trial period. There may well be an as-
certainment bias as the sickest patients are more likely
to want to change their life, whereas several of the
stable patients were not keen to participate. Most pre-
viously published studies of dietary interventions in
this disorder have, therefore examined short-term or
retrospective data, rather than using a randomised
controlled trial design [4,14,30,31]. Any future trial
should recognise these problems in their design. The
dose selected in this study was one that is commonly
used by patients treated with corn-starch but the
Bhattacharya et al. Orphanet Journal of Rare Diseases  (2015) 10:18 Page 10 of 11optimal dose of WMHMS may well be different. As a
consequence, formal dosing studies should be per-
formed to ascertain the best treatment regimen of the
new starch. It was our hope that any reduction in
starch use would be matched by a broadening of
dietary range approaching recommendations for peers.
This aspect of the study was observational and no such
alterations took place, with the 2 subjects taking less
starch, taking less overall energy. This may reflect the
narrow dietary range that these subjects have learnt to
adhere to, as well as the relatively short length of the
study. Dietary advice has been given after the conclu-
sion of this trial, in the hope that a broader range of
foods would be taken. Typically many patients have a
set dietary routine and repertoire of responses to
hypoglycaemia from which they find it difficult to devi-
ate [24,32]. As a consequence, dietary advice in GSD I
should be dynamic and supportive, incorporating
physiological changes that occur over time but still un-
derstanding patients’ resistance to change.
This study has demonstrated an improved glucose and
insulin profile after 50 g of WMHMS was given when com-
pared to UCCS. The study provides preliminary data that
the starch can be safely introduced into the dietary regimen
of patients without untoward effects. Further studies deter-
mining mechanism of action, role in other disorders,
optimal dosing and long-term effects should be performed.Competing interests
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